Registry of cell therapy for non-ischemic dilated cardiomyopathy
Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy
This study collects information from patients with non-ischemic dilated cardiomyopathy who received their own cell therapy to see how well it works over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | University Medical Centre Ljubljana Academic / other |
| Locations | 1 site (Ljubljana) |
| Trial ID | NCT02445534 on ClinicalTrials.gov |
What this trial studies
This registry collects long-term clinical data from patients with non-ischemic dilated cardiomyopathy who have undergone autologous cell therapy. Patients treated at UMC Ljubljana between January 2005 and January 2018 will be followed up in a dedicated heart failure outpatient clinic. The aim is to analyze the data periodically to identify predictors of response to cell therapy, enhancing understanding of its long-term benefits.
Who should consider this trial
Good fit: Ideal candidates for this registry are adults aged 18-65 with a diagnosis of dilated cardiomyopathy and specific functional and clinical criteria.
Not a fit: Patients with acute multi-organ failure or a history of hematologic neoplasms will not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could help identify which patients are most likely to benefit from cell therapy, potentially improving treatment outcomes.
How similar studies have performed: Previous studies have shown beneficial effects of stem cell therapy in similar patient populations, but this registry aims to provide more definitive long-term data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient inclusion criteria consisted of the following: age 18-65 years old, diagnosis of DCM according to the European Society of Cardiology position statement (9), optimal medical management for at least 6 months, left ventricular ejection fraction (LVEF) \<40%, and New York Heart Association functional Class III on stable medical therapy for at least 3 months before referral. Exclusion Criteria: * Patients with acute multi-organ failure or a history of hematologic neoplasms were not included.
Where this trial is running
Ljubljana
- UMC Ljubljana — Ljubljana, Slovenia (Recruiting)
Study contacts
- Principal investigator: Bojan Vrtovec, MD, PhD — UMC Ljubljana
- Study coordinator: Bojan Vrtovec, MD, PhD
- Email: bojan.vrtovec@gmail.com
- Phone: +3861 522 1157
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.